Atarax
The new drug Antegren is slated to have multi uses. The drug is effective against Crohn's disease as well as multiple sclerosis. The drug was tested with human patients who had one of the diseases and patients reported significant reduction in their symptoms. Crohn's disease can be a painful and troublesome disease because it affects the proper functioning of the digestive system. MS on the other hand, is thought to be an autoimmune disorder where nerves in the central nervous system are destroyed, disrupting many different functions. A person's vision, hearing, talking and walking may be affected. Crohn's disease is related to bowel and stomach disorders caused by inflammation. The person with Crohn's may have stomach pain, gas and bowel disruption. In both diseases, inflammation plays a key role. In MS cytokines are involved in flare ups resulting in inflammation of nerve fibres, whose myelin coating becomes damaged. Damage to nerve fibers results in communication becoming impaired. Several drugs, including steroids and anti-spasmodic agents are used to try and make a flare-up subside. Antegren is the brand name of natalizumab being jointly developed by Biogen and Elan for world wide marketing. It is given to the patient by injection. New drugs on the scene, ie: Zocor, are oral and anti-inflammatory medications. Antegren was 30% more effective than placebo in trials with both diseases. Newer drugs may achieve the goal of slowing disease progression with few side effects. The year 2005 should bring good news for MS and Crohn's sufferers who need new therapies.
Excitatory amino acid transporter 1, glutamic acid, oxidation reduction reaction, vesicular glutamate transporter 1, 265 - functional magnetic resonance imaging, language, 268 - glutamic acid, potassium channel, seizure, 301 - health care utilization, medical audit, 459 - hemoglobin, oxygenation, seizure, 447 - Human immunodeficiency virus infection, neurologic disease, seizure, 346 - inborn error of metabolism, 477 - intellect, language, mother, 340 - ion channel, 317 - lamotrigine, valproic acid, 275 - learning disorder, 494 - magnetoencephalography, seizure, 418 - manic psychosis, 255 - memory, 254 - mood disorder, 475 - neuroprotection, 281 - nuclear magnetic resonance imaging, stereoelectroencephalography, 331 - oxcarbazepine, pregabalin, seizure, sleep apnea syndrome, 469 - parasomnia, 259 - patient monitoring, reminder system, 299 - pediatrics, social problem, 495 - progesterone, sialic acid, 390 - psychosis, 258 - psychosis, schizophrenia, 490 - quality of life, seizure, 352 - seizure, 329 - seizure, sudden death, 333 - social discrimination, stigma, 496 - toxoplasmosis, 271 - visuomotor coordination, 256 epileptic aura, migraine aura, 314 epileptic discharge, epilepsy, 251 epileptic focus, congenital blood vessel malformation, 472 - optical tomography, seizure, 404 epileptic state, 282 375 - 4 aminobutyric acid, seizure, 324 - anesthetic agent, 279 - anticonvulsant activity, carbamazepine, kainic acid, seizure, 398 - anticonvulsive agent, emergency care, 311 - barbituric acid derivative, propofol, 470 - basic fibroblast growth factor, 343 - benzodiazepine receptor, epileptogenesis, flunitrazepam, lithium chloride, mu opiate receptor, pilocarpine, 379 - camphor, 428 - cognitive defect, 482 - complex partial seizure, Hashimoto encephalopathy, 466 - convulsion, 458 - dentate gyrus, 493 - diazepam, dizocilpine, metabotropic receptor 5, metabotropic receptor antagonist, 2 methyl 6 phenylethynyl ; pyridine, 373 - disease classification, 278 - epilepsy, 283 - furan derivative, lipid, oxygen, 400 - gene, potassium channel Kv1.1, 289 - intensive care unit, 280 - osteomyelitis, 423 - seizure, 304 439 - seizure, traumatic brain injury, 319 - transcutaneous nerve stimulation, 396 epileptogenesis, benzodiazepine receptor, epileptic state, flunitrazepam, lithium chloride, mu opiate receptor, pilocarpine, 379 - pyriform cortex, 262 - stress, 383 etiracetam, anticonvulsant therapy, myoclonus epilepsy, 441 - brain hypoxia, brivaracetam, myoclonus seizure, 392 - carbamazepine, epilepsy, lamotrigine, topiramate, valproic acid, 294 - epilepsy, 356 - epilepsy, topiramate, 345 Section 50 vol 41.2.
Barrois, B., M. Carles, et al. 2007 ; . "Efficacy and tolerability of hyaluronan ialuset ; in the treatment of pressure ulcers: a multicentre, non-randomised, pilot study." Drugs in R & D 267-73. BACKGROUND: Pressure ulcers are complex chronic wounds and a frequent cause of morbidity in elderly subjects in hospitals and nursing homes. Local treatment is based on the use of dressings that protect the wound and provide a favourable environment for healing to occur. ialuset, a treatment based on hyaluronan hyaluronic acid ; , is already available on the market and known to be an effective treatment for venous leg ulcers. However, no clinical trials of hyaluronan as a treatment option for pressure ulcers have been reported as yet. METHODS: The purpose of this review was to investigate the efficacy and.
Atarax suspension
B. Venous thromboembolism VTE ; . In the PREMPRO substudy of WHI, a 2-fold greater rate of VTE, including deep venous thrombosis and pulmonary embolism, was observed in women receiving PREMPRO compared to women receiving placebo. The rate of VTE was 34 per 10, 000 woman-years in the PREMPRO group compared to 16 per 10, 000 woman-years in the placebo group. The increase in VTE risk was observed during the first year and persisted. See CLINICAL PHARMACOLOGY, Clinical Studies. ; If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization. 2. Malignant neoplasms. a. Breast cancer. Estrogen progestin therapy in postmenopausal women has been associated with an increased risk of breast cancer. In the PREMPRO substudy of the Women's Health Initiative study, a 26% increase of invasive breast cancer 38 vs 30 per 10, 000 woman-years ; after an average of 5.2 years of treatment was observed in women receiving PREMPRO compared to women receiving placebo. The increased risk of breast cancer became apparent after 4 years on PREMPRO. The women reporting prior postmenopausal use of estrogen and or estrogen with progestin had a higher relative risk for breast cancer associated with PREMPRO than those who had never used these hormones. See CLINICAL PHARMACOLOGY, Clinical Studies. ; Epidemiologic studies have reported an increased risk of breast cancer in association with increasing duration of postmenopausal treatment with estrogens, with or without progestin. This association was reanalyzed in original data from 51 studies that involved treatment with various doses and types of estrogens, with and without progestin. In the reanalysis, an increased risk of having breast cancer diagnosed became apparent after about 5 years of continued treatment, and subsided after treatment had been discontinued for about 5 years. Some later studies have suggested that treatment with estrogen and progestin increases the risk of breast cancer more than treatment with estrogen alone. A postmenopausal woman without a uterus who requires estrogen should receive estrogen-alone therapy and should not be exposed unnecessarily to progestins. All postmenopausal women should receive yearly breast exams by a healthcare provider and perform monthly breast selfexaminations. In addition, mammography examinations should be scheduled based on patient age and risk factors. b. Endometrial cancer. The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12-fold greater than in nonusers, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with the use of estrogens for less than one year. The greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for five to ten years or more, and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.
Atarax hydroxyzine side effects
Atarax hydroxyzine 2hcl
Health resource home disclaimer news forum library writer about medicine pharmacy health resources drug information, and health articles find a drug: select a product aciphex acyclovir albenza aldactone aldara alesse allegra amitriptyline allegra d amoxicillin antivert aphthasol atarax bentyl buspar buspirone bupropion butalbital-apap carisoprodol celebrex celexa cialis clarinex claritin-d cleocin-t gel colchicine condylox cyclobenzaprine denavir detrol la diflucan diprolene af dovonex effexor xr elavil elidel elimite esgic plus estradiol eurax evista famvir fioricet flexeril flextra ds flonase fluoxetine fosamax gris-peg imitrex ionamin kenalog kenalog aerosol lamisil oral levbid levitra lexapro lipitor microzide mircette motrin naprosyn nasacort aq nasonex nexium nizoral norvasc ortho evra ortho tricyclen ortho tricyclen lo osteoporosis patanol paxil paxil cr penlac phendimetrazine phentermine phenterprin hcl prevacid prilosec propecia protopic prozac ranitidine hcl remeron renova retin-a seasonale skelaxin soma sumycin synalar synalar cream tamiflu temovate tenuate tetracycline tramadol tretinoin transderm scop triphasil ultracet ultram valtrex vaniqa vermox viagra wellbutrin wellbutrin sr xenical yasmin zanaflex zithromax zoloft zovirax zyban zyloprim zyrtec health resources health resources what is genital herpes and precose. IMAGING OF MUELLER-WEISS SYNDROME: A CASE STUDY OF ADULT-ONSET AVASCULAR NECROSIS OF THE NAVICULAR BONE. V. Venu, G. Andrews, University of British Columbia, Vancouver, BC, Canada. Introduction: Adult-onset spontaneous osteonecrosis of the navicular bone is a rare disorder known as Mueller-Weiss syndrome. Patients with this disorder present with a painful clinical course and progressive deformity. Koehler's disease, spontaneous osteochondrosis of the navicular bone in children, is a separate entity, and should not be confused with Mueller-Weiss syndrome. These disorders differ not only in age at onset but also in clinical outcome and radiological findings. Mueller first described osteonecrosis of the navicular bone in adults and summarized his radiological findings as medial and or dorsal protrusion of the navicular bone associated with collapse of the lateral aspect of the bone. Current literature suggests both early and late radiological changes. Initially there is loss of volume and increased radiodensity observed in the lateral aspect of the navicular bone. This is followed by a comma-shaped navicular bone and dorsal protrusion and fragmentation. Fracture lines may also be visualized on CT, and a homogeneous decrease in signal intensity of the navicular bone can be seen on T1-weighted MR images. Discussion: Here we present an interesting case of adult-onset avascular necrosis of the navicular bone. The patient's initial presentation, diagnostic work-up, and radiological findings will be discussed. Conclusion: Mueller-Weiss syndrome is a difficult diagnosis to make. However, diagnosis can be aided by radiological images especially with CT and MR guidance. We present this case in the hope of increasing awareness of this disease and to demonstrate some of the common radiological findings that can be used to aid diagnosis. Nicorandil n 185 ; Placebo n 183 ; 85 46.4 ; 76 41.5 ; 21 11.5 ; 1 0.5 ; 137 18 22 ; 32 17.4 ; 150 82.0 ; 89.5 23.2 8.1 Kaplan-Meier estimates for all patients: Coronary heart disease death or unplanned hospital admission for congestive heart failure. P 0.53 89 48.1 ; 82 44.3 ; 13 7.0 ; 1 0.5 ; 137 19 25 ; 30 16.2 ; 154 83.2 ; 88.6 23.9 8.3 and torsemide. 191. K.vanderPutten1, R.A Man2, H hreuder1, C.A.J.M.Gaillard1 1 Meander Medical Centre, Department of Internal Medicine, PO Box 1502, 3800 BM AMERSFOORT, the Netherlands, e-mail: k.vander.putten meandermc.nl, 2Erasmus Medical Centre, ROTTERDAM, the Netherlands. Injection, verteporfin 0.1mg Visudyne Injection triflupromazine HCl up to 20mg Vesprin Injection Vistaril hydroxyzine up to Hyzine-50 25mg Atarwx Injection thiamine HCL 200mg Thiamilate and glucophage!
Request. At the completion of the study, remaining CeaVac and TriAb supplies should be inventoried and destroyed on site. Immunotherapy Information Drug Classification Biological response modifier Mode of Action Immunomodulatory; direct effects Availability 2 mg vial; free to study patients from Titan Pharmaceuticals, Inc. Storage Refrigerate at 2-8o C Do Not Freeze ; Shelf Life Two years at refrigeration Stability After Withdrawal from Vial 30 minutes at room temperature Vaccine Administration Vaccines will be supplied in vials and will require no reconstitution prior to injection. The step by step instructions for the intracutaneous intradermal ; and subcutaneous administrations of the CeaVac and TriAb vaccines to be injected at separate sites in different arms ; are as follows: 1 ; Prepare the injection site by cleansing an area of skin on the upper arm deltoid ; with an alcohol swab and allow the skin to dry. Use clean needle for each patient injection. 2 ; Withdraw the study drug from the vial 2 mg dose from 2 mg 1ml vial ; and expel all bubbles and air from the syringe. 3 ; Expel any overfill to ensure a volume in the syringe of 1 ml. 4 ; Stretch the skin taught at the injection site and insert the needle with the bevel at a 45 angle or less. 5 ; The needle should come to rest in the dermis for the initial three weekly intracutaneous injections ; or just below it for the subsequent monthly subcutaneous injections ; . 6 ; A small bleb should form at the injection site. Continue to inject until the entire solution has been administered. 7 ; Quickly withdraw the syringe needle and discard appropriately. 8 ; Gently blot any solution on the skin surface with gauze pads or paper tissue. 9 ; Repeat this procedure steps 1-8 ; with the other vaccine in the other arm. 10 ; Observe the patient for 30 minutes, and instruct the patient not to scratch or apply pressure to the injection site for 30 minutes. Vital signs should be recorded at 15 and 30 minutes post injection. 11 ; At 30 minutes, the injection site should be observed for signs of local irritation, and any reaction should be recorded appropriately if present. A bandage may be applied, if needed. 12 ; All previous injection sites should be observed and any adverse events recorded at each visit. Document the date time and site left vs. right arm ; of each injection. Inject drug within 30 minutes after withdrawal from the vial. Expected Toxicities and Management of Immunotherapy The most likely immunization side effects anticipated in this study are local skin reaction, fever, chills, and sweats as the direct effect of antibody. These seldom require therapy and persist for only a few hours. Anti-pruritics will be used symptomatically post therapy. Premedication with anti-pruritics or steroids will be avoided. The injections will continue despite these symptoms. Ice packs or heat applications to the injection sites will be avoided due to the potential change in the drug's absorption rate. The next most likely side effects are urticaria and or pruritus secondary to allergic reactions to mouse protein. They may be treated symptomatically with diphenhydramine Benadryl ; or hydroxyzine Tarax ; but prophylactic administration of these is not recommended. Therapy will be continued despite the appearance of urticaria or pruritus. Ice packs or heat applications to the injection sites will be avoided due to the potential change in the drug's absorption rate. Less common but more severe allergic reactions include bronchospasm and anaphylaxis. In the presence of these, treatment should be immediately discontinued and the patient treated with epinephrine, steroids, oxygen, volume support, other bronchodilators such as theophylline as needed, and other supportive care as needed. The injections will not be resumed. Uncommon mild to moderate side effects include nausea, vomiting, diarrhea, and increased serum transaminases. These generally require no specific therapy and resolve spontaneously. Theoretically, immune complex disease as manifested by skin, joint, renal, or other manifestations could occur, but these should be rare in the absence of prior exposure to mouse protein. More severe 8.
For test methods, please refer to the product data sheets listed in table 1 and actoplus. Empty select from list aciphex acomplia actos adalat albenza aldactone allegra altace amaryl amoxil ampicillin arava arcoxia atacand atarax atropisol atrovent avandia avapro aygestin bactrim benzac biaxin breast success capoten carafate cardizem cardura casodex caverta ceclor celebrex celexa chloromycetin cialis cialis soft tabs cipro clarinex claritin cleocin clomid colospa cordarone coreg coumadin cozaar crestor danocrine deltasone depakote desyrel diamox diflucan diltiazem diltiazem hci diovan ditropan doxycycline duphaston duricef ed trial pack effexor xr elavil enhance9 euphoria cologne euphoria perfume evista exelon feldene female rx oil female rx plus flagyl flomax florinef floxin fosamax geodon gestanin glucophage glucotrol xl hoodia gordonii hoodia patch human growth agent hydrea hytrin ilosone imdur imodium imuran inderal inderal la indocin isoptin isordil joint formula kamagra kamagra oral jelly keflex lamisil oral lasix levaquin levitra lexapro lioresal lipitor liquid rx plus lopressor lotensin lozol luvox maxolon mevacor mexitil microzide minipress minocin motilium motrin multi vitamin naprosyn neurontin nexium nimotop nizoral nolvadex norplant norvasc ortho tri-cyclen pamelor parlodel paxil pepcid periactin persantine phenergan plavix plendil ponstel prandin pravachol premarin premium diet patch prevacid prilosec propecia protonix provera proviron prozac pulmicort rebetol reglan retrovir rheumatrex risperdal rulide serevent silagra sinequan singulair soma sumycin super greens suprax symmetrel synthroid tadalis sx tamiflu tegretol tenormin tofranil topamax trecator-sc ultram vasotec verapamil viagra viagra soft tabs viramune virility patch rx virility pills voltaren voltarol vprx oil yerba diet zanaflex zantac zebeta zerit zero nicotine patch zestril zithromax zocor zofran zoloft zovirax zyban zyprexa zyrtec allergies anthelmintics anti bacterial anti depressants anti fungal anti-convulsants anti-viral antibiotics arthritis asthma blood pressure cancer cholesterol diabetes digestive diseases diuretics gastrointestinal heart diseases heartburn herbal hypertension lung diseases men' s health migraines muscle relaxant neurologic diseases pain relief skin care stop smoking thyroid weight loss women' s health delivery was successful. Chemicals have been based upon the assumption that "the dose-make the poison", which implies that high doses invariably cause more harm than lower doses. It has been a surprise to regulators to learn that for hormonally active chemicals, this assumption may not be valid. Endocrinologists and physicians have known for and actos. Just like any other decision equipment, weather, etc. ; that you must make when you fly, you should know all the facts before you can answer this question. There are several things that you need to know and take into account before you make the go no-go decision. Add these to your check list: First, consider the underlying condition that you are treating. What will be the consequences if the medication doesn't work or if it wears off before the flight is over? A good general rule to follow is not to fly if you must depend on the medication to keep the flight safe. In other words, if the untreated condition is one that would prevent safe flying, then you shouldn't fly until the condition improves -- whether you take the medication or not. Second, you must consider your reaction to the medication. There are two broad categories of medication reactions. One is a unique reaction based on an individual's biological make-up. Most people don't have such reactions but anyone can, given the right medication. Because of this, you should NEVER fly after taking any medication that you have not taken before. It is not until after you have taken the medication that you will find out whether you have this uncommon and unexpected reaction to the medication. 1. Pimozide: mean dose 6mg day, range 2-10mg. N 16. 2. Fluphenazine oral: mean dose mean 7.5mg day, range 3-21mg. N 16. 3. Group psychotherapy: last 8 weeks, 8 per drug group. As required benzotropine for EPS allowed and avandamet. Apoptosis in femoral head sections from patients diagnosed with avascular necrosis [Weinstein et al., 1998b]. Osteocytes remain connected to osteoblasts and lining cells by processes that extend through channels in the lamellar bone called canaliculi [Buckwalter et al., 1996a]. The network of osteocytes and canaliculi may have an important mechanosensory role in detecting microdamage and directing the remodeling process [Shapiro, 1988; Weinstein and Manolagas, 2000]. Therefore, increased osteocyte apoptosis may lead to an accumulation of microdamage and the development of atraumatic fractures. In summary, the primary mechanism of glucocorticoid-induced osteoporosis is most likely an inhibition of bone formation, resulting from reductions in osteoblast number and metabolic activity Table 1.1 ; . The cummulative effects of reduced osteoblast recruitment, inhibited osteoblast proliferation, and increased osteoblast apoptosis by glucocorticoids are a decreased rate of new bone formation and a loss of healthy bone. For those osteoblasts still available to form bone, glucocorticoids inhibit IGF-I expression and type I collagen synthesis.
Rh blood group antigen compositions and methods of use, Inventors: L. Scott Rodkey, Marwan A. Yared, Kenneth J. Moise, Jr., Patent # 5, 840, 585, issued November 24, 1998 Patent # 6, 551, 830 B2, issued April 22. 2003. November 1998 and avandia and Buy atarax online.
Atarax tab 25 mg
Song J, Walsh MF, Igwe R et al. Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2 + currents and not endothelial nitric oxide production. Diabetes. 1997; 46: 659-664 and glucotrol. Administer Benadryl tsp. or Ata4ax tsp. Swish & Swallow Administer Call 911, transport to ER if symptoms occur, for evaluation, treatment and observation x 4 hours. The survey found an almost even distribution between women 52.6% ; and men 47.4% ; in terms of microfinance beneficiaries across the country see Table 2 ; . It likely, however, that without a conscientious effort on the part of donors to promote female participation, the present situation could have been considerably different. The survey shows that there are four programmes CMN, Kukula, Project Hope and The Hunger Project ; that exclusively target women, collectively accounting for 9, 035 clients. Other programmes such as Ophavela PCRs ; operating in Nampula Province, were initially heavily dominated by male members but, following considerable promotion, there is now almost equal gender participation. Despite such successes, gender disparities remain and are clearly evidenced in programmes serving the South and North. The disparity was clearly demonstrated when the FCC programme was extended to the North. In the South female clients outnumbered men by a factor of two to one. In the North, using the same methodology, the FCC struggled to attain 15% female participation. Larger credit programmes in the North such as the First Microfinance Programme and CCCPCCOM Cabo Delgado ; continue to show that, despite concerted efforts to promote greater female participation, the former has managed a 28% female participation while the latter, operating in rural areas, only achieved 12.6%. In contrast, CCOM Maputo ; operating in suburbs of Maputo-Matola has almost three quarters 73.5% ; female participation. Regional differences have usually been attributed to socio-economic, cultural and religious differences. Given that savings deposits have only been recently introduced by microfinance operators, it is too early to comment on gender patterns although there are early indications that men are much more likely to open up savings accounts than women. In December, 2005 NovoBanco had 41, 689 deposit accounts the vast majority being current ; of which only about a third belong to womento women. 2.5.6 Distribution of Microfinance Operators and Outreach Table 4 and Map 1 demonstrate the extent of regional disparity of microfinance provision see Annex 3 for details by operator ; . The Maputo-Matola axis alone is served by 14 operators who supply credit to more than half 50.8% ; of nation's active micro-borrowers. Because of the higher average loan size in the Maputo area in particular from NovoBanco and SOCREMO ; these borrowers receive a proportionately higher percentage 58% ; of the active portfolio. Because of the significant impact of PCR programmes and the recent introduction of savings products, the Maputo area is only responsible for 39.1% of the active savers. However, the rapid growth of new savings accounts with NovoBanco and the recent introduction of savings products by SOCREMO, it can be predicted that the number of savers will increase rapidly, especially in the Maputo-Matola area. The Beira Corridor traversing Sofala and Manica provinces ; has received comparatively large investments by the three commercial banks NovoBanco, SOCREMO and BOM ; and the PCR programmes AKSM and ADEM ; . The corridor now accounts for 11.7% of the nation's MFI borrowers and almost 18% of the savers. The disparity of microfinance provision may at first seem to be unreasonably skewed. However, an analysis of the distribution of non-agricultural informal activities at least partially explains the apparent distortion. The preliminary data published by the Instituto Nacional de Estatistca INE ; of its informal sector survey69 show that of the non-agricultural informal sector activities, 42% of those involved in trading and 48% of those involved in services excluding transport ; are located in the province of Maputo or Maputo City.
You may choose to purchase coverage for your dependents who are eligible for health benefits with the State in , 000 increments up to half of your coverage amount up to a maximum of 0, 000 ; . You may choose up to , 000 guaranteed coverage for eligible dependents without a medical history statement. If you select coverage greater than , 000 for a dependent, a medical history statement for that dependent must be completed and reviewed by The Standard. PLEASE NOTE.
What is atarax used for in dogs
Atadax, atsrax, atarad, a6arax, ztarax, ataraz, ataarax, ataraax, ata4ax, starax, ataeax, ata5ax, xtarax, atara, wtarax, qtarax, taarax, atarx, ataax, atzrax, aharax, atxrax, atarrax, atarac, atwrax.Atarax generic form
Atarax suspension, atarax hydroxyzine side effects, atarax hydroxyzine 2hcl, atarax tab 25 mg and what is atarax used for in dogs. Atarad generic form, atarax 25 mg tabs, atarax uk and atarax effects or is atarax safe.
Atarax 25 mg tabs
Annotation examples, gingivitis pictures, alkaline phosphatase optimum temperature, measles symptoms adults and essential lifestyle planning. Catalyst ventures, pregnancy symptoms 4 5 weeks, autotransplantation and iritis causes or infertile blonde.
© 2005-2008 Work.bigfreehost.net, Inc. All rights reserved.
